Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Ovarian Neoplasms 5Neoplasms 5Neoplasm Metastasis 5Fallopian Tube Neoplasms 4Carcinoma 4Carcinoma, Renal Cell 3Sarcoma 2Glioblastoma 2Gastrointestinal Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Brain Neoplasms 2Stomach Neoplasms 1Sarcoma, Endometrial Stromal 1Renal Insufficiency 1Rectal Neoplasms 1Prostatic Neoplasms 1Oligodendroglioma 1Melanoma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Kidney Neoplasms 1Kidney Diseases 1Hemangiosarcoma 1Gliosarcoma 1Glioma 1Congenital Abnormalities 1

Interventions

Cytarabine 68fludarabine phosphate 59Peripheral Blood Stem Cell Transplantation 51Cyclophosphamide 48Busulfan 46Tacrolimus 36Mycophenolic Acid 35Etoposide 33Cyclosporine 32Methotrexate 29Whole-Body Irradiation 28Antilymphocyte Serum 28Filgrastim 27Flow Cytometry 22Mitoxantrone 19Radiotherapy 18Daunorubicin 18Melphalan 16Idarubicin 16sargramostim 13Gene Expression Profiling 12Clofarabine 12Polymerase Chain Reaction 11Methylprednisolone 11Decitabine 10Cord Blood Stem Cell Transplantation 10merphos 9Transplantation 9Immunologic Techniques 9Granulocyte Colony-Stimulating Factor 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Congenital Abnormalities × trebananib × Clear all
NCT01555268 2022-09-13

Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia

Roswell Park Cancer Institute

Phase 1 Completed
24 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡